Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Other EventsItem 8.01 Other Events.
On July27, 2017, Trovagene,Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for PCM-075, a Polo-like Kinase 1 (PLK1) inhibitor, and has provided authorization to proceed with the treatment of patients with AML. A copy of the press release is furnished as Exhibit99.1 to this Form8-K.
Item 9.01. Financial Statements and Exhibits
(d)Exhibits.
99.1 Press Release of Trovagene,Inc. dated July27, 2017
Trovagene, Inc. ExhibitEX-99.1 2 a17-18382_2ex99d1.htm EX-99.1 Exhibit 99.1 Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia PCM-075,…To view the full exhibit click here
About Trovagene,Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
